This page uses content from Wikipedia and is licensed under CC BY-SA.
|Bleeding Disorders (Coagulopathy)|
|Classification and external resources|
A bleeding disorder (coagulopathy) is a condition that affects the way the blood clots. It is characterised by prolonged/excessive bleeding following injury or medical and dental procedures. In some instances spontaneous bleeding can occur into joints, muscles or other parts of the body. Irregular clotting can be due to deficiencies and defects in blood platelets and/or clotting factors. The body produces 13 clotting factors. Blood clotting is affected if any of the clotting factors are deficient or defective.
Bleeding disorders can be inherited or acquired. Some bleeding disorders can occur due to conditions such as anemia, vitamin K deficiency, leukemia, cirrhosis of the liver and HIV. They also can result from certain medications that are used to thin the blood, including antiplatelet and anticoagulant medications. Platelets are a components of blood that stop bleeding by clotting blood at the site of blood vessel injuries.
Examples of inherited bleeding disorders include Haemophilia A, Haemophilia B and von Willebrand Disease. Bleeding disorders can be acquired due to antiplatelet and anticoagulant medications that are taken for the prophylaxis and treatment of medical conditions such as atrial fibrillation, deep vein thrombosis (DVT), Stroke, Pulmonary Embolism and heart attack. Examples of these medications include Aspirin and Clopidogrel (antiplatelets), Warfarin (anticoagulant) and Novel Oral Anticoagulant medications (NOACs) such as Rivaroxaban, Apixaban and Dabigatran.
Signs of bleeding disorders include:
Coagulopathy may cause excessive external and/or internal bleeding. Uncontrolled bleeding may cause damage to internal organs, joints and muscles. If this is left untreated it may be life-threatening.
Additional signs and symptoms of Thrombocytopenia include:
Acetylsalicylic acid (Aspirin)
Drugs marked with * only have a mild inhibiting effect on the platelet function, which may increase bleeding slightly.
Apixaban, Rivaroxaban and Dabigatran (NOACs) are included in the list of drugs that can cause bleeding.
The normal clotting process depends on the interplay of various proteins in the blood called clotting factors. Coagulopathy may be caused by reduced levels or absence of blood-clotting proteins, known as clotting factors or coagulation factors. Genetic disorders, such as hemophilia and Von Willebrand's disease, can cause a reduction in clotting factors.
Anticoagulants such as warfarin will also prevent clots from forming properly. Coagulopathy may also occur as a result of dysfunction or reduced levels of platelets (small disk-shaped bodies in the bloodstream that aid in the clotting process).
Warfarin is a vitamin K antagonist. It decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase which blocks vitamin K activation. In turn, clotting factors II, VII, IX, and X have decreased clotting ability.
Rivaroxaban is an anticoagulant and is a direct factor Xa inhibitor.
Apixaban is an anticoagulant - factor Xa inhibitor for the prevention and treatment of thromboembolic diseases.
Aspirin inhibits platelet function by acetylation of the platelet cyclooxygenase (COX).
Routine screening tests include:
The PTT or APTT is a medical test that characterises blood coagulation (clotting). The PTT and PT tests are also used to monitor oral anticoagulant therapy such as Warfarin. People who take Warfarin will have their INR routinely monitored to ensure it is within the therapeutic range. The longer it takes blood to clot, the higher the INR will be.
The PTT is used in conjunction with another test that measures how quickly blood clotting takes place called the prothrombin time (PT). The prothrombin time measures the speed of clotting by means of the extrinsic pathway (also known as the tissue factor pathway).
Hemophilia is diagnosed by measuring the level of factor activity in a blood sample:
Testing for von Willebrand Disease involves measuring the level and activity of VWF, and that of another blood clotting protein, factor VIII (FVIII). in an individual's blood.
If someone has coagulopathy, their health care provider may help them manage their symptoms with medications or replacement therapy. In replacement therapy, the reduced or absent clotting factors are replaced with proteins derived from human blood or created in the laboratory. This therapy may be given either to treat bleeding that has already begun or to prevent bleeding from occurring.
For people who require rapid reversal of warfarin in cases of serious bleeding or emergency surgery, the effects of warfarin can be reversed with vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP). Blood products should not be routinely used to reverse warfarin overdose when vitamin K could work alone.
Treatment for haemophilia requires the missing clotting factor to be administered into the bloodstream. People with mild hemophilia A may sometimes use desmopressin (also called DDAVP) to treat minor bleeding. DDAVP is a synthetic hormone that stimulates the release of factor VIII.
VWD can be treated with Desmopressin or with a clotting factor concentrate that contains VWD.
One area of treatment is managing people with major bleeding in a critical setting, like an emergency department. In these situations, the common treatment is transfusing a combination of red cells with one of the following options:
The use of tranexamic acid is the only option that is currently supported by a large, randomized, controlled clinical trial, and is given to people with major bleeding after trauma. There are several possible risks to treating coagulopathies, such as transfusion-related acute lung injury, acute respiratory distress syndrome, multiple organ dysfunction syndrome, major hemorrhage, and venous thromboembolism.
|Condition||Prothrombin time||Partial thromboplastin time||Bleeding time||Platelet count|
|Vitamin K deficiency or warfarin||Prolonged||Normal or mildly prolonged||Unaffected||Unaffected|
|Disseminated intravascular coagulation||Prolonged||Prolonged||Prolonged||Decreased|
|Von Willebrand disease||Unaffected||Prolonged or unaffected||Prolonged||Unaffected|
|Liver failure, early||Prolonged||Unaffected||Unaffected||Unaffected|
|Liver failure, end-stage||Prolonged||Prolonged||Prolonged||Decreased|
|Factor V deficiency||Prolonged||Prolonged||Unaffected||Unaffected|
|Factor X deficiency as seen in amyloid purpura||Prolonged||Prolonged||Unaffected||Unaffected|
|Bernard-Soulier syndrome||Unaffected||Unaffected||Prolonged||Decreased or unaffected|
|Factor XII deficiency||Unaffected||Prolonged||Unaffected||Unaffected|